Quantum-Si Incorporated - Class A Common Stock (QSI)
1.9900
+0.0300 (1.53%)
Quantum-Si Inc is a company focused on advancing the field of protein sequencing technology
By leveraging innovative next-generation approaches, it aims to provide researchers and scientists with more efficient and accurate tools for sequencing proteins, which are essential for understanding biological processes and developing new therapeutics. Its proprietary platform integrates advanced imaging and computational techniques to capture detailed data on protein structures, facilitating breakthroughs in genomics and personalized medicine. Quantum-Si's mission is to enhance life sciences research and improve the capability to analyze complex biological materials, which has significant implications for healthcare and biotechnology.
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, and IDEX Health & Science, LLC., today announced they will partner on the development and manufacturing of the optics module for Quantum-Si’s novel proteomics platform, Proteus™.
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, announces its participation in the upcoming Festival of Genomics UK, taking place on January 29–30, 2025, at ExCeL London. As part of the event, Richard Broadhead, Ph.D., will deliver a presentation highlighting the latest innovations in Next-Generation Protein Sequencing™ and its transformative impact on proteomics and multiomics research.
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted 44,893 restricted stock units (“RSUs”) to new employees under the Company’s previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the “2023 Inducement Plan”). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4).
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, announces the launch of Platinum® Pro, its latest benchtop sequencer that sets a new standard in protein analysis. Designed to redefine efficiency and versatility in proteomics research, Platinum Pro is now available for ordering.
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, announces the release of its latest preprint titled “Protein Barcoding and Next-Generation Protein Sequencing for Multiplexed Protein Selection, Analysis, and Tracking.” This study highlights the potential of integrating Quantum-Si’s benchtop Platinum® instrument with an innovative protein barcoding workflow, offering a sensitive and accessible approach to multiplexed protein analysis.
The first weekend of 2025 has been a whirlwind in the world of finance, with cryptocurrencies making significant strides. Bitcoin (CRYPTO: BTC) is inching closer to the $100,000 mark, while Dogecoin has seen a surge, possibly due to Elon Musk’s influence.
On Friday, Cathie Wood-led Ark Invest made significant trades involving PLTR, ARKB, and QSI. The PLTR trade sold shares worth $1.6 million, aligning with Ark's trend of reducing their position in the hot AI stock.
Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 15,625,000 shares of common stock at a purchase price of $3.20 per share, pursuant to a registered direct offering, resulting in gross proceeds of approximately $50 million, before deducting placement agent commissions and other offering expenses. The closing of the offering is expected to occur on or about January 6, 2025, subject to the satisfaction of customary closing conditions.
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced a new paper that was submitted to BioRxiv, demonstrating the capabilities of its proprietary bioinformatics tool called ProteoVue, for detecting and quantifying Single Amino Acid Variants (SAAVs). The paper, titled “Detecting Amino Acid Variants Using Next-Generation Protein Sequencing (NGPS),” highlights the transformative potential of Quantum-Si’s Platinum® benchtop instrument in advancing proteomics research and applications. The full preprint publication will be available soon on the BioRxiv website.
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted 46,666 restricted stock units (“RSUs”) to new employees under the Company’s previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the “2023 Inducement Plan”). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4).
